文献速递妇科

全面手术分期在临床早期上皮性卵巢癌中的归因价值:系统综述与荟萃分析

The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: A systematic review and meta-analysis.
PubMed 文献 · Gynecol Oncol · 2021-04-10

该系统综述与荟萃分析纳入23项研究、共5194例临床I或II期上皮性卵巢癌患者,量化全面手术分期各步骤的肿瘤阳性率与升级率。总体升级率为18.7%(95%CI 14.1-23.4%),浆液性组织学和高分级肿瘤升级率最高,分别为35.3%和40.9%。全面手术分期在临床早期EOC中仍具重要归因价值。

要点

  • 临床早期EOC全面分期后总体升级率为18.7%。
  • 浆液性组织学和高分级肿瘤升级率最高(35.3%和40.9%)。
  • 淋巴结受累导致升级率为8.7%。

核心结论

  • 全面手术分期在临床早期EOC患者中仍具重要归因价值,尤其在浆液性和高分级肿瘤中。

研究设计与样本

  • 系统检索PubMed、Embase和Cochrane Library,纳入23项研究,共5194例临床I或II期EOC患者,均接受全面手术分期。
  • 采用Newcastle-Ottawa量表评估偏倚风险,使用逆方差加权随机效应模型计算合并比例和95%CI。

主要发现

  • 临床早期EOC患者总体升级率为18.7%(95%CI 14.1-23.4%)。
  • 浆液性组织学和高分级EOC升级率最高,分别为35.3%(95%CI 21.8-48.7%)和40.9%(95%CI 35.6-46.2%)。
  • 淋巴结受累导致升级率为8.7%(95%CI 6.2-11.3%)。
  • 子宫、细胞学、腹膜活检、大网膜和阑尾的肿瘤阳性率分别为6.2%(95%CI 1.8-10.7%)、18.4%(95%CI 13.8-22.9%)、9.7%(95%CI 3.8-15.6%)、5.2%(95%CI 1.7-8.8%)和3.6%(95%CI 0.0-7.5%)。
  • 上述部位对应的升级率分别为5.9%(95%CI 1.4-10.4%)、8.5%(95%CI 1.8-15.2%)、3.5%(95%CI 1.0-6.0%)、3.9%(95%CI 1.4-6.3%)和1.6%(95%CI 0.0-3.4%)。

关键数值与推荐

  • 临床早期EOC全面分期后总体升级率为18.7%(95%CI 14.1-23.4%)。
  • 浆液性组织学升级率为35.3%(95%CI 21.8-48.7%),高分级肿瘤升级率为40.9%(95%CI 35.6-46.2%)。
  • 淋巴结受累升级率为8.7%(95%CI 6.2-11.3%)。

临床怎么用

  • 对临床早期EOC患者,尤其是浆液性或高分级肿瘤,应重视全面手术分期的实施以准确判断分期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumor positivity and upstaging rates from various surgical staging steps performed in clinically early-stage epithelial ovarian carcinoma (EOC) vary widely in literature. AIM: To quantify tumor positivity and upstaging rates for all staging surgery steps in EOC patients. Differences between subgroups based on their clinical and histological characteristics are explored. METHODS: A systematic search using synonyms of 'ovarian cancer', 'neoplasm staging', and 'neoplasm metastasis' was conducted in PubMed, Embase, and the Cochrane Library. Meta-analysis was performed on 23 included studies, comprising 5194 clinical stage I or II EOC patients who underwent comprehensive surgical staging. Studies were assessed using the Newcastle-Ottawa Scale risk-of-bias tool. Pooled proportions and 95% confidence intervals were calculated using an inverse variance weighted random-effects model. RESULTS: Overall upstaging rate of clinically early-stage EOC patients was 18.7% (95%CI: 14.1-23.4%). Serous histology or high grade EOC showed the highest upstaging rate at 35.3% (95%CI: 21.8-48.7%) and 40.9% (95%CI: 35.6-46.2%). Lymph node involvement resulted in an upstaging rate of 8.7% (95%CI: 6.2-11.3%). Tumor was identified in uterus, cytology, peritoneal biopsies, omentum and appendix in 6.2% (95%CI: 1.8-10.7%), 18.4% (95%CI: 13.8-22.9%), 9.7% (95%CI: 3.8-15.6%), 5.2% (95%CI: 1.7-8.8%) and 3.6% (95%CI: 0.0-7.5%) of EOC patients. The corresponding upstaging rates were 5.9% (95%CI: 1.4-10.4%), 8.5% (95%CI: 1.8-15.2%), 3.5% (95%CI: 1.0-6.0%), 3.9% (95%CI: 1.4-6.3%) and 1.6% (95%CI: 0.0-3.4%), respectively. CONCLUSION: The attributive value of comprehensive surgical staging in clinically early-stage EOC patients remains substantial, particularly in serous and high grade tumors.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. van de Vorst REWM, Hoogendam JP, van der Aa MA, et al. The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: A systematic review and meta-analysis. Gynecol Oncol. 2021. PMID: 33849726. doi:10.1016/j.ygyno.2021.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。